{"id":"akt","name":"AKT","symbol":"AKT1/2/3","route":"/targets/akt/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142208","uniprot":"https://www.uniprot.org/uniprotkb/P31749/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P31749","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4282","open-targets":"https://platform.opentargets.org/target/ENSG00000142208","civic":"https://civicdb.org/genes/207/summary","oncokb":"https://www.oncokb.org/gene/AKT1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AKT1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=AKT1","depmap":"https://depmap.org/portal/gene/AKT1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000142208-AKT1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/207","omim":"https://www.omim.org/entry/164730"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:392","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105221","uniprot":"https://www.uniprot.org/uniprotkb/P31751/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P31751","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2431","open-targets":"https://platform.opentargets.org/target/ENSG00000105221","civic":"https://civicdb.org/genes/208/summary","oncokb":"https://www.oncokb.org/gene/AKT2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AKT2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=AKT2","depmap":"https://depmap.org/portal/gene/AKT2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000105221-AKT2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/208","omim":"https://www.omim.org/entry/164731"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:393","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117020","uniprot":"https://www.uniprot.org/uniprotkb/Q9Y243/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q9Y243","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4816","open-targets":"https://platform.opentargets.org/target/ENSG00000117020","civic":"https://civicdb.org/genes/10000/summary","oncokb":"https://www.oncokb.org/gene/AKT3","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AKT3","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=AKT3","depmap":"https://depmap.org/portal/gene/AKT3?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000117020-AKT3","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/10000","omim":"https://www.omim.org/entry/611223"}],"products":[{"id":"capivasertib","name":"Capivasertib","status":"approved","modality":"Small-molecule AKT inhibitor","route":"/drugs/capivasertib/"},{"id":"everolimus","name":"Everolimus","status":"approved","modality":"Small-molecule mTOR inhibitor","route":"/drugs/everolimus/"},{"id":"gedatolisib","name":"Gedatolisib","status":"approved","modality":"Small-molecule pan-PI3K/mTOR inhibitor","route":"/drugs/gedatolisib/"},{"id":"ipatasertib","name":"Ipatasertib","status":"phase-3","modality":"small molecule","route":"/drugs/ipatasertib/"}],"trials":[{"id":"nct03997123","name":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","nct":"NCT03997123","phase":"3","status":"active"},{"id":"capitello-281","name":"CAPItello-281","nct":"NCT04493853","phase":"3","status":"positive"},{"id":"compete","name":"COMPETE","nct":"NCT03049189","phase":"3","status":"positive"},{"id":"evera","name":"evERA","nct":"NCT05306340","phase":"3","status":"positive"},{"id":"ipatunity130","name":"IPATunity130","nct":"NCT03337724","phase":"3","status":"negative"},{"id":"litespark-005","name":"LITESPARK-005","nct":"NCT04195750","phase":"3","status":"positive"},{"id":"capitello-291","name":"CAPItello-291","nct":"NCT04305496","phase":"3","status":"positive"},{"id":"clear","name":"CLEAR (KEYNOTE-581)","nct":"NCT02811861","phase":"3","status":"positive"},{"id":"checkmate-025","name":"CheckMate 025","nct":"NCT01668784","phase":"3","status":"positive"},{"id":"bolero-2","name":"BOLERO-2","nct":"NCT00863655","phase":"3","status":"positive"},{"id":"radiant-3-4","name":"RADIANT-3 and RADIANT-4","nct":"NCT00510068","phase":"3","status":"positive"},{"id":"nct06764186","name":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","nct":"NCT06764186","phase":"3","status":"active"},{"id":"nct05862285","name":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","nct":"NCT05862285","phase":"3","status":"recruiting"},{"id":"nct04862663","name":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","nct":"NCT04862663","phase":"3","status":"active"},{"id":"nct06635447","name":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","nct":"NCT06635447","phase":"3","status":"active"},{"id":"nct05918302","name":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","nct":"NCT05918302","phase":"3","status":"recruiting"},{"id":"nct05501886","name":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","nct":"NCT05501886","phase":"3","status":"active"},{"id":"nct04919226","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","nct":"NCT04919226","phase":"3","status":"active"},{"id":"nct06757634","name":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","nct":"NCT06757634","phase":"3","status":"recruiting"},{"id":"nct05348577","name":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)","nct":"NCT05348577","phase":"3","status":"active"},{"id":"nct07165886","name":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","nct":"NCT07165886","phase":"2/3","status":"recruiting"},{"id":"nci-match","name":"NCI-MATCH (EAY131)","nct":"NCT02465060","phase":"platform","status":"active"},{"id":"cupisco","name":"CUPISCO","nct":"NCT03498521","phase":"2","status":"positive"},{"id":"national-lung-matrix-trial","name":"National Lung Matrix Trial","nct":"NCT02664935","phase":"2","status":"completed"},{"id":"pakt","name":"PAKT","nct":"NCT02423603","phase":"2","status":"positive"},{"id":"plasmamatch","name":"plasmaMATCH","nct":"NCT03182634","phase":"2","status":"completed"},{"id":"lotus","name":"LOTUS","nct":"NCT02162719","phase":"2","status":"positive"},{"id":"nct04931342","name":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","nct":"NCT04931342","phase":"2","status":"active"},{"id":"barbican","name":"BARBICAN","nct":"NCT05498896","phase":"2","status":"active"},{"id":"nct06301386","name":"Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients","nct":"NCT06301386","phase":"2","status":"planned"},{"id":"nct07340541","name":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","nct":"NCT07340541","phase":"2","status":"recruiting"},{"id":"nct05749588","name":"FUSCC Refractory TNBC Platform Study (FUTURE2.0)","nct":"NCT05749588","phase":"2","status":"recruiting"},{"id":"nct06428396","name":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","nct":"NCT06428396","phase":"2","status":"active"},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","nct":"NCT05725200","phase":"2","status":"recruiting"},{"id":"nct04589845","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","nct":"NCT04589845","phase":"2","status":"active"},{"id":"nct03742102","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","nct":"NCT03742102","phase":"1/2","status":"active"},{"id":"nct07002177","name":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","nct":"NCT07002177","phase":"1/2","status":"recruiting"},{"id":"nct04802759","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","nct":"NCT04802759","phase":"1/2","status":"recruiting"},{"id":"nct03424005","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","nct":"NCT03424005","phase":"1/2","status":"recruiting"},{"id":"nct06190899","name":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","nct":"NCT06190899","phase":"1/2","status":"recruiting"},{"id":"nct05563220","name":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","nct":"NCT05563220","phase":"1/2","status":"active"},{"id":"nct05573126","name":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","nct":"NCT05573126","phase":"1/2","status":"recruiting"},{"id":"nct07287917","name":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","nct":"NCT07287917","phase":"1/2","status":"recruiting"}],"pathways":["aml-signalling","cml-signalling","glutamine-metabolism","lipid-metabolism-cancer","melanoma-signalling","mrna-translation-eif4f","nsclc-signalling","pi3k-akt-mtor","prostate-cancer-signalling","sclc-signalling"],"companies":["astrazeneca","celcuity","novartis","roche-genentech"],"keyPapers":["paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026","paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021","paper-schmid-pakt-capivasertib-tnbc-jco-2020","paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018","paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017","paper-ferraldeschi-pten-protein-loss-abiraterone-eur-urol-2015","paper-carver-pi3k-ar-reciprocal-feedback-prostate-cancer-cell-2011"],"hotspots":[{"label":"E17K","position":17,"kind":"activating","frequency":"About 3 to 5% of breast cancers","drugs":["capivasertib"]}],"openQuestions":[],"assays":[],"resistance":[{"class":"cdk46-endocrine","mechanism":"PI3K/AKT/mTOR activation","category":"bypass"},{"class":"ar-pathway","mechanism":"AR amplification and ligand-binding-domain mutations","category":"on-target"},{"class":"ar-pathway","mechanism":"AR splice variants (AR-V7)","category":"on-target"},{"class":"ar-pathway","mechanism":"Lineage plasticity to neuroendocrine prostate cancer","category":"lineage"},{"class":"ar-pathway","mechanism":"PI3K/AKT activation via PTEN loss","category":"bypass"},{"class":"ar-pathway","mechanism":"Glucocorticoid receptor substitution","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}